Skip to main content
Caplight Logo









ImmunoGenesis

ImmunoGenesis

Private
Houston, TexasHealthcare & Life Scienceshttps://immunogenesis.com

Last Round

Grant

Dec 4, 2025

Total Funding Raised

$70.7M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ImmunoGenesis operates in Healthcare & Life Sciences and is based in Houston, Texas. Its latest recorded funding round was a Grant round in December 2025.

ImmunoGenesis is a biopharmaceutical company that develops immuno-oncology therapeutics designed to enhance immune responses in cold tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

ImmunoGenesis Comparables

Compare ImmunoGenesis with similar companies based on industry and business-model similarity.

ImmunoGenesis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Incendia Therapeutics
87%
Isosceles Pharmaceuticals
81%
BioEclipse Therapeutics
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

ImmunoGenesis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 4, 2025
Series AApr 1, 2024
VC RoundJun 27, 2023
GrantAug 19, 2020
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

ImmunoGenesis Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 55% MoM.

  • Apr 15, 2026

    Poster presentation at the AACR 2026 Annual Meeting.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • hiresSep 9, 2026

    Immunogenesis, Inc. appoints Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors in Texas on Sep 9th '26.

  • hiresSep 9, 2026

    On Sep 9th '26, Immunogenesis, Inc. appoints Reza Mazhari to its Board of Directors in Texas, alongside Mike Davis, at a pivotal time for the company.

  • hiresSep 9, 2026

    Immunogenesis, Inc. appoints Mike Davis to its Board of Directors alongside Reza Mazhari in Texas on Sep 9th '26.

  • hiresSep 9, 2026

    Immunogenesis, Inc. appoints Mike Davis to its Board of Directors in Texas on Sep 9th '26, alongside Reza Mazhari, as the company advances its pipeline, partnering and fundraising strategy.

Book a demo to see all news

For institutional investors. Book with your work email.

ImmunoGenesis Filings

Explore SEC and related filing metadata, where available.

ImmunoGenesis filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about ImmunoGenesis's valuation, stock price, and market status.

Is ImmunoGenesis a public or private company?

ImmunoGenesis is a private company.

What is the current stock price of ImmunoGenesis?

ImmunoGenesis is a private company, so its shares have no public market price. Caplight tracks ImmunoGenesis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is ImmunoGenesis worth (valuation)?

Valuation information for ImmunoGenesis is not publicly available.

Can I buy ImmunoGenesis stock?

ImmunoGenesis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was ImmunoGenesis's last funding round?

ImmunoGenesis's most recent funding round was Grant on December 4, 2025.

Who are the main investors in ImmunoGenesis?

Key investors in ImmunoGenesis include Cancer Focus Fund, Cancer Prevention and Research Institute of Texas (CPRIT).

Will ImmunoGenesis IPO soon?

No public IPO plans have been announced for ImmunoGenesis.

How can I track ImmunoGenesis secondary market activity?

Caplight tracks bids, offers, and trades in ImmunoGenesis's shares on secondary markets.

Firmographic Details

HeadquartersHouston, Texas
Employee Range11
Year Founded2019
Last FundingDec 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?